March 2026 Research Update

This month, studies of oral approaches added two different kinds of evidence: a larger real-world snapshot for eliglustat in Gaucher disease type 1, and an early signal that ambroxol might help some neurologic symptoms in Gaucher disease type 3 when added to enzyme therapy. Across these studies, the clearest, most consistent change was in blood and biomarker measures, while nervous system symptoms were addressed only in a small, single-arm study and improved only in some people. Together, these results add to the picture that oral options are being explored for different parts of Gaucher disease, but the strength of evidence still varies a lot by drug and by disease type. [1] [2]

In 19 adults with Gaucher disease type 1 in China followed for about 6 to 9 months on eliglustat alone, the disease-related blood marker lyso-Gb1 dropped from 468 to 210 ng/mL, and platelet counts increased. Liver and spleen volumes also decreased over follow-up, while hemoglobin changes were smaller and not clearly different from baseline in the full group. This supports the idea that, in routine care, eliglustat can coincide with measurable improvements in key Gaucher markers over months. The reduction in lyso-Gb1 was larger in patients who had not previously received enzyme replacement therapy. [1]

Safety reporting for eliglustat in a larger group (90 people) found suspected drug-related side effects in 27.8%, mostly mild stomach or skin issues, with no serious events or treatment stops reported in that dataset. This adds practical context about what side effects were seen in this setting, although the summary does not describe how long each person was followed for safety. [1]

For neuronopathic Gaucher disease type 3, a small study of 13 Polish patients on stable enzyme replacement therapy reported that adding ambroxol for one year reduced the severity of selected neurologic symptoms in several patients, and lowered two commonly followed Gaucher biomarkers (chitotriosidase and lyso-GL1). Because there was no control group described, the study cannot separate how much change was due to ambroxol versus natural ups and downs or other factors, but it does provide a concrete signal to study further. [2]

A separate single-patient report looked at eliglustat in Saposin C deficiency (a related condition where a helper protein needed for glucocerebrosidase function is missing). Over 9 years, the patient had improvements in organ enlargement, blood measures, biomarkers, and bone density, but seizures did not improve. This is not Gaucher disease type 1 or 3, but it adds to the broader idea that reducing substrate build-up with eliglustat may help some lysosomal storage conditions while not necessarily addressing neurologic symptoms. [3]

For patients and caregivers, the strongest near-term message this month is that eliglustat in Gaucher disease type 1 was linked with a clear drop in a Gaucher blood marker and with improvements in some blood counts and organ size measures over several months in a small real-world group. The ambroxol results matter more as early research, because only 13 people were studied and changes were compared mainly to baseline, but it helps clarify that some neurologic symptoms and Gaucher biomarkers may move in a positive direction when this add-on approach is tried. The single-patient Saposin C report helps clarify that even when body and blood measures improve, seizures may not change, which is important context for what different treatments might and might not affect. What remains uncertain is how these findings compare against similar patients not receiving these drugs, and how durable the changes are over longer periods. [1] [2] [3]

This month added building blocks for how Gaucher-related enzymes are measured and modeled, rather than reporting new patient outcomes. One large study established expected ranges for glucocerebrosidase activity in healthy adults, which supports clearer interpretation of this lab test when it is used. Other laboratory studies explored how enzyme activity might be increased using mRNA delivery and clarified structural details of a related enzyme system that may help future modeling. [4] [5] [6]

In 530 healthy adults, leukocyte (white blood cell) glucocerebrosidase activity had a median of 2.29 nmol/10^7 cells/h, with a wide reference interval (0.093 to 8.945). Activity was slightly lower after age 45 and was higher in females, and it was not meaningfully related to hemoglobin, blood group, or body weight in this dataset. This helps clarify that normal values vary widely and that age and sex can shift results, which may matter when interpreting borderline lab values. [4]

In cell and mouse experiments, optimized human GBA1 mRNA constructs produced much higher glucocerebrosidase activity in cells than less efficient versions, and the enzyme reached lysosomes (the cell compartment where it is needed). In mice, a single lipid nanoparticle dose led to detectable enzyme activity in liver and spleen within 72 hours. This does not show that the approach will work in people, but it helps clarify technical steps that would be needed for an mRNA-based strategy to be plausible. [5]

A structural biology study mapped the 3D shape of a plant glucosylceramidase (AtGCD3) and described how parts of the protein form hydrophobic channels that can hold the fatty tails of glucosylceramide in simulations. The authors present this as a template for modeling human GBA2, a different glucosylceramide-processing enzyme relevant to sphingolipid biology. For Gaucher families, this is foundational research that aims to make future drug design and enzyme modeling more precise, but it is far from clinical testing. [6]

These studies mainly matter by improving the tools and concepts behind Gaucher testing and future therapy development. The reference ranges for enzyme activity may matter sooner, because they can support clearer interpretation of a commonly used enzyme test and highlight that age and sex can shift results. The mRNA and structural studies are early laboratory work; they help clarify what might be technically achievable, but they do not predict patient benefit yet. What remains uncertain is how these lab findings translate into real-world diagnosis accuracy or into treatments that are safe and effective in humans. [4] [5] [6]

This month included a single detailed report of a person with Gaucher disease who developed a specific blood cancer that changed form during treatment. It adds a real-life example of how complex care can become when Gaucher disease and leukemia overlap, including the need to balance cancer control with medication side effects. Because it is one person, it cannot estimate risk or what most patients should expect, but it documents what was observed and how it was managed in this case. [7]

The report describes a 54-year-old man with Gaucher disease type 1 (splenectomized and on enzyme replacement therapy) who developed Philadelphia chromosome-positive chronic myeloid leukemia and later transformed to B-lymphoblastic leukemia during tyrosine kinase inhibitor therapy. After treatment with an EWALL protocol plus dasatinib, remission was reported, and the patient later switched to bosutinib after developing a large pleural effusion attributed to dasatinib. The case also discussed how Gaucher-related cells can resemble "pseudo-Gaucher" changes in bone marrow, which can complicate interpretation when blood cancers are present. [7]

For patients and caregivers, this report mainly adds understanding rather than changing anything now. It shows that if a blood cancer occurs in someone with Gaucher disease, treatments may involve multiple targeted cancer drugs and can include serious side effects that require switching medicines, at least in some situations. It also helps clarify that bone marrow findings can be harder to interpret because Gaucher-related cells and cancer-related changes can look similar. What remains uncertain is how often situations like this happen in Gaucher disease, because a single case cannot answer risk questions. [7]